The many "small COPDs": COPD should be an orphan disease

Stephen I. Rennard, Jørgen Vestbo

Research output: Contribution to journalComment/debate

74 Citations (Scopus)

Abstract

COPD is one of the most common causes of morbidity and mortality. Perhaps paradoxically, COPD also should be an orphan disease. Importantly, this could advance the development of treatments for COPD. There are two criteria for orphan status in the United States. Most widely known is the criterion of < 200,000 affected individuals; however, secondarily, is the impossibility for development costs to be recovered during the patent life of a product. COPD should qualify for the first criterion if the various conditions that comprise COPD are regarded separately. The subphenotyping of COPD into separate groups based on mechanism sets the stage for the rational development of therapeutics. In addition, many candidate treatments may alter the natural history of COPD. Testing them, however, will require large studies for a duration that will compromise the commercial life of any resulting product. Orphan status, therefore, could facilitate the development of treatments for both phenotypic subsets of COPD patients as well as aid the development of agents to alter the natural history of the disease. Post-drug approval regulations could require that agents approved under the orphan provisions are prospectively monitored, assuring that rigorous longitudinal data are generated. This approach could encourage the pharmaceutical industry to stratify studies based on a more detailed characterization of study subjects at baseline, thus approaching "many small COPDs" instead of a single large and heterogeneous COPD. This strategy may help to address the increasing burden that COPD presents and for which no novel clinical class of treatment has been introduced for 30 years.

Original languageEnglish (US)
Pages (from-to)623-627
Number of pages5
JournalChest
Volume134
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Rare Diseases
Chronic Obstructive Pulmonary Disease
Orphaned Children
Therapeutics
Drug Approval
Drug and Narcotic Control
Drug Industry
Morbidity
Costs and Cost Analysis
Mortality

Keywords

  • COPD
  • Drug therapy
  • Phenotype

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

The many "small COPDs" : COPD should be an orphan disease. / Rennard, Stephen I.; Vestbo, Jørgen.

In: Chest, Vol. 134, No. 3, 09.2008, p. 623-627.

Research output: Contribution to journalComment/debate

Rennard, SI & Vestbo, J 2008, 'The many "small COPDs": COPD should be an orphan disease', Chest, vol. 134, no. 3, pp. 623-627. https://doi.org/10.1378/chest.07-3059
Rennard, Stephen I. ; Vestbo, Jørgen. / The many "small COPDs" : COPD should be an orphan disease. In: Chest. 2008 ; Vol. 134, No. 3. pp. 623-627.
@article{98453b9587bd42f7b7535a57b4bca875,
title = "The many {"}small COPDs{"}: COPD should be an orphan disease",
abstract = "COPD is one of the most common causes of morbidity and mortality. Perhaps paradoxically, COPD also should be an orphan disease. Importantly, this could advance the development of treatments for COPD. There are two criteria for orphan status in the United States. Most widely known is the criterion of < 200,000 affected individuals; however, secondarily, is the impossibility for development costs to be recovered during the patent life of a product. COPD should qualify for the first criterion if the various conditions that comprise COPD are regarded separately. The subphenotyping of COPD into separate groups based on mechanism sets the stage for the rational development of therapeutics. In addition, many candidate treatments may alter the natural history of COPD. Testing them, however, will require large studies for a duration that will compromise the commercial life of any resulting product. Orphan status, therefore, could facilitate the development of treatments for both phenotypic subsets of COPD patients as well as aid the development of agents to alter the natural history of the disease. Post-drug approval regulations could require that agents approved under the orphan provisions are prospectively monitored, assuring that rigorous longitudinal data are generated. This approach could encourage the pharmaceutical industry to stratify studies based on a more detailed characterization of study subjects at baseline, thus approaching {"}many small COPDs{"} instead of a single large and heterogeneous COPD. This strategy may help to address the increasing burden that COPD presents and for which no novel clinical class of treatment has been introduced for 30 years.",
keywords = "COPD, Drug therapy, Phenotype",
author = "Rennard, {Stephen I.} and J{\o}rgen Vestbo",
year = "2008",
month = "9",
doi = "10.1378/chest.07-3059",
language = "English (US)",
volume = "134",
pages = "623--627",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - The many "small COPDs"

T2 - COPD should be an orphan disease

AU - Rennard, Stephen I.

AU - Vestbo, Jørgen

PY - 2008/9

Y1 - 2008/9

N2 - COPD is one of the most common causes of morbidity and mortality. Perhaps paradoxically, COPD also should be an orphan disease. Importantly, this could advance the development of treatments for COPD. There are two criteria for orphan status in the United States. Most widely known is the criterion of < 200,000 affected individuals; however, secondarily, is the impossibility for development costs to be recovered during the patent life of a product. COPD should qualify for the first criterion if the various conditions that comprise COPD are regarded separately. The subphenotyping of COPD into separate groups based on mechanism sets the stage for the rational development of therapeutics. In addition, many candidate treatments may alter the natural history of COPD. Testing them, however, will require large studies for a duration that will compromise the commercial life of any resulting product. Orphan status, therefore, could facilitate the development of treatments for both phenotypic subsets of COPD patients as well as aid the development of agents to alter the natural history of the disease. Post-drug approval regulations could require that agents approved under the orphan provisions are prospectively monitored, assuring that rigorous longitudinal data are generated. This approach could encourage the pharmaceutical industry to stratify studies based on a more detailed characterization of study subjects at baseline, thus approaching "many small COPDs" instead of a single large and heterogeneous COPD. This strategy may help to address the increasing burden that COPD presents and for which no novel clinical class of treatment has been introduced for 30 years.

AB - COPD is one of the most common causes of morbidity and mortality. Perhaps paradoxically, COPD also should be an orphan disease. Importantly, this could advance the development of treatments for COPD. There are two criteria for orphan status in the United States. Most widely known is the criterion of < 200,000 affected individuals; however, secondarily, is the impossibility for development costs to be recovered during the patent life of a product. COPD should qualify for the first criterion if the various conditions that comprise COPD are regarded separately. The subphenotyping of COPD into separate groups based on mechanism sets the stage for the rational development of therapeutics. In addition, many candidate treatments may alter the natural history of COPD. Testing them, however, will require large studies for a duration that will compromise the commercial life of any resulting product. Orphan status, therefore, could facilitate the development of treatments for both phenotypic subsets of COPD patients as well as aid the development of agents to alter the natural history of the disease. Post-drug approval regulations could require that agents approved under the orphan provisions are prospectively monitored, assuring that rigorous longitudinal data are generated. This approach could encourage the pharmaceutical industry to stratify studies based on a more detailed characterization of study subjects at baseline, thus approaching "many small COPDs" instead of a single large and heterogeneous COPD. This strategy may help to address the increasing burden that COPD presents and for which no novel clinical class of treatment has been introduced for 30 years.

KW - COPD

KW - Drug therapy

KW - Phenotype

UR - http://www.scopus.com/inward/record.url?scp=51649091911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649091911&partnerID=8YFLogxK

U2 - 10.1378/chest.07-3059

DO - 10.1378/chest.07-3059

M3 - Comment/debate

C2 - 18779197

AN - SCOPUS:51649091911

VL - 134

SP - 623

EP - 627

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -